
|Videos|October 13, 2017
Dr. Ginsburg on Determining Genetic Testing in Gynecologic Malignancies
Author(s)Ophira M. Ginsburg, MSc, MD, FRCPC
Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.
Advertisement
Women in families with MSH2 germline mutation for Lynch syndrome need to be counseled, especially if they test positive for the mutation, states Ginsburg. These women have a very high risk of uterine cancer and endometrial cancer. Additionally, the risk of uterine cancer in those families is higher than the risk of ovarian cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5




































